Methotrexate Iontophoresis Versus Methotrexate 1% Gel on Depigmentation in Vitiligo Patients

N/ANot Yet RecruitingNCT07208890

Pharos University in Alexandria30 enrolled

Overview

Vitiligo is a common autoimmune depigmenting disorder characterized by selective destruction of melanocytes. Methotrexate (MTX) has shown potential in stabilizing disease activity and promoting repigmentation; however, systemic administration may cause hepatotoxicity. This pilot study aims to compare the efficacy and safety of methotrexate iontophoresis versus topical methotrexate 1% gel in patients with vitiligo. Thirty patients will be randomly assigned into two equal groups: Group A will receive methotrexate iontophoresis (5-10 mA, 15 min/session) for 8 weeks, while Group B will apply methotrexate 1% gel twice daily for 8 weeks. Outcomes will be assessed using the Vitiligo Area and Severity Index (VASI) and the Vitiligo Impact Scale-22 (VIS-22), with liver function monitored monthly

Vitiligo is an autoimmune depigmenting disorder characterized by melanocyte destruction. Methotrexate (MTX) has shown potential in modulating autoimmune activity and promoting repigmentation, but systemic use carries hepatotoxic risks. This pilot randomized study compares methotrexate iontophoresis and topical methotrexate 1% gel in stable vitiligo patients. Thirty participants will be assigned equally into two groups: the iontophoresis group will receive MTX via low-intensity electric current sessions for 8 weeks, while the control group will apply topical MTX gel twice daily for the same period. Efficacy will be evaluated using the Vitiligo Area and Severity Index (VASI) and quality of life by the Vitiligo Impact Scale-22 (VIS-22). Liver function will be monitored monthly to ensure safety

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria:Clinically diagnosed vitiligo confirmed by a dermatologist. Stable vitiligo for at least 6 months (no new lesions or progression). Age between 18 and 60 years. Both male and female patients. Presence of localized or segmental vitiligo suitable for topical treatment. Willingness to avoid other vitiligo treatments (e.g., phototherapy, corticosteroids) during the study period. Able and willing to provide written informed consent and comply with study procedures - Exclusion Criteria:History of systemic or topical methotrexate use within the past 3 months. Unstable or rapidly progressive vitiligo during the last 6 months. Presence of other autoimmune or dermatologic disorders that could interfere with study evaluation (e.g., psoriasis, eczema, lupus). Known hypersensitivity or allergy to methotrexate or any gel/iontophoresis components. Hepatic, renal, or hematologic impairment (abnormal liver function or renal profile). Pregnant or breastfeeding women, or those planning pregnancy during the study period. Use of phototherapy, corticosteroids, or immunosuppressive therapy within the last 3 months. Metal implants or pacemakers, which may contraindicate iontophoresis \-

Outcomes

Primary Outcomes

Vitiligo Area and Severity Index (VASI

in Vitiligo Area and Severity Index (VASI) from baseline to week 8 to evaluate the degree of repigmentation

Time frame: 2 month

Vitiligo Impact Scale-22 (VIS-22)

quality of life measured by the Vitiligo Impact Scale-22 (VIS-22), percentage of repigmentation in target lesions, and the proportion of participants achieving ≥50% repigmentatio

Time frame: 2month